Search results for "VASCULAR RISK"

showing 10 items of 328 documents

Resistin: a new marker of cardiorenal risk?

2010

Riskbusiness.industryBioinformaticsCardiovascular riskDiabetes ComplicationsCardiovascular DiseasesInternal MedicineMedicineAlbuminuriaHumansResistinResistinbusinessUrinary albumin excretionMicroalbuminuria
researchProduct

Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome

2014

In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). W…

Riskmedicine.medical_specialtyOrganic Cation Transport ProteinsOrganic anion transporter 1Uric acid pre-hypertension metabolic sindrome cardiovascular metabolismGlucose Transport Proteins FacilitativeOrganic Anion TransportersHyperuricemia030204 cardiovascular system & hematologymetabolic syndromePrehypertensionPrehypertension03 medical and health scienceschemistry.chemical_compound0302 clinical medicineuric acidInternal medicinemedicineAnimalsHumanspre-hypertensionHyperuricemiaMetabolic SyndromePharmacologyOrganic cation transport proteinsbiologybusiness.industryMedicine (all)Glucose transporterCardiovascular riskmedicine.diseaseUric AcidMetabolic pathwayMetabolismEndocrinologychemistrybiology.proteinUric acidMetabolic syndromeCardiology and Cardiovascular MedicinebusinessPre-hypertensionmetabolism030217 neurology & neurosurgeryCurrent Vascular Pharmacology
researchProduct

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.

2022

Guidelines have increasingly stressed the concept that adequate glycemic control is required to prevent or decrease the macro- and microvascular complications of type 2 diabetes mellitus (T2DM). PPAR-gamma agonists (“glitazones”) are no longer prioritized due to their effects on heart failure. However, the association between these drugs and innovative therapies could be a valuable tool to attenuate the risk factors of the metabolic syndrome. Glitazones are used for the treatment of diabetes and associated comorbidities. There is substantial scientific evidence demonstrating the effect of glitazones at a cardiometabolic level, as well as on hematological and neurological pathologies that po…

RosiglitazoneDiabetes Mellitus Type 2PioglitazonePeroxisome Proliferator-Activated ReceptorsHumansHypoglycemic AgentsThiazolidinedionescardiovascular risk metabolic syndrome pioglitazone type 2 diabetes mellitusGeneral MedicineMedicina (Kaunas, Lithuania)
researchProduct

A nationwide cross-sectional epidemiological study of cardiovascular risk factors as a tool for management of primary and secondary prevention in Lat…

2021

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): EUROPEAN SOCIAL FUND MINISTRY OF HEALTH, LATVIA Background. An increasing prevalence (PREV.) of noncomunicable diseases is a major public health concern  in Latvia. Regular nationwide epidemiological studies present an opportunity to estimate the dinamics of PREV of health risk factors (RF) and thus assist in planning resources and improving prevention strategies at national level. Objective.  The aim  was to analyze the PREV of cardiovascular  RF identified in a  epidemiological study in 2019-2020. To assess changes in RF prevalence, the results were compared to data from a simi…

Secondary preventionmedicine.medical_specialtyPrimary (chemistry)Epidemiologybusiness.industryEnvironmental healthCardiovascular risk factorsEpidemiologyMedicineCardiology and Cardiovascular MedicinebusinessEuropean Journal of Preventive Cardiology
researchProduct

Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers.

2019

The prevalence of several diseases increases by age, including cardiovascular diseases, which are the leading cause of morbidity and mortality worldwide. Aging, as a complex process characterized by senescence, triggers various pathways, such as oxidative stress, systemic inflammation, metabolism dysfunction, telomere shortening, mitochondrial dysfunction and deregulated autophagy. A better understanding of the mechanisms underlying senescence may lead to the development of new therapeutic targets and strategies for age-related pathologies and extend the healthy lifespan. Modulating lifestyle risk factors and adopting healthy dietary patterns remain significant tools in delaying the aging …

SenescenceAgingmedia_common.quotation_subjectCardioprotectionDisease030204 cardiovascular system & hematologyDiabeteBioinformaticsSystemic inflammation03 medical and health sciences0302 clinical medicineRisk FactorsCardiovascular DiseaseDiabetes mellitusDrug DiscoveryMedicineHumansLife Style030304 developmental biologymedia_commonPharmacologyCardioprotection0303 health sciencesbusiness.industryRisk FactorLongevityCardiovascular riskmedicine.diseaseMetabolic syndromeDietCardiovascular DiseasesLife expectancyQuality of LifeNutraceuticalMetabolic syndromemedicine.symptombusinessHumanCurrent pharmaceutical design
researchProduct

Telomere length and cardiovascular disease

2010

SummaryTelomeres are structures composed of deoxyribonucleic acid repeats that protect the end of chromosomes, but shorten with each cell division. They have been the subject of many studies, particularly in the field of oncology, and more recently their role in the onset, development and prognosis of cardiovascular disease has generated considerable interest. It has already been shown that these structures may deteriorate at the beginning of the atherosclerotic process, in the onset and development of arterial hypertension or during myocardial infarction, in which their length may be a predictor of outcome. As telomere length by its nature is a marker of cell senescence, it is of particula…

SenescenceGenetic Markersmedicine.medical_specialtyCell divisionDiseaseBioinformaticsmedicine.disease_causeTélomèreInternal medicinemedicineAnimalsHumansFacteurs de risque cardiovasculairesMyocytes CardiacMyocardial infarctionRisk factorCellular SenescenceCardiovascular risk factorsMaladies cardiovasculairesbusiness.industryStress oxydatifGeneral MedicineTelomeremedicine.diseaseTelomereEndocrinologyCardiovascular diseasesGene Expression RegulationGenetic markerOxidative stressEndothelium VascularbusinessCardiology and Cardiovascular MedicineOxidative stressArchives of Cardiovascular Diseases
researchProduct

Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause

2013

Context: Polycystic ovary syndrome (PCOS) is diagnosed during the reproductive years when women present with 2 of 3 of the following criteria: 1) irregular menstrual cycles or anovulation, 2) hyperandrogenism, and 3) PCO morphology. However, there is evidence that PCOS can be identified from early infancy to puberty based on predisposing environmental influences. There is also increasing information about the PCOS phenotype after menopause. The goal of this review is to summarize current knowledge about the appearance of PCOS at different life stages and the influence of reproductive maturation and senescence on the PCOS phenotype. Evidence: PubMed, the bibliography from the Evidence-Based …

Senescencemedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryContext (language use)BiochemistrySettore MED/13 - EndocrinologiaAnovulationEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaInternal medicinemedicinePregnancybusiness.industryPolycystic ovary syndrome (PCOS)Biochemistry (medical)Hyperandrogenismnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryPCOS Pregnancy infancy puberty menopause obesity AMH cardiovascular risk birth weightSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsMenopauseEndocrinologybusiness
researchProduct

Consensus On Women'S Health Aspects Of Polycystic Ovary Syndrome (Pcos)

2012

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females with a high prevalence. The etiology of this heterogeneous condition remains obscure and its phenotype expression varies. Two, widely cited, previous ESHRE/ASRM-sponsored PCOS consensus workshops focused on diagnosis (published in 2004) and infertility management (published in 2008). The present third PCOS consensus paper summarizes current knowledge and identifies knowledge gaps regarding various women's health aspects of PCOS. Relevant topics addressed-all dealt with in a systematic fashion-include adolescence, hirsutism and acne, contraception, menstrual cycle abnormalities, quality of life, ethnicity, preg…

Settore MED/09 - Medicina InternaConsensus Development Conferences as TopicmenopauseType 2 diabetesSettore MED/13 - EndocrinologiaQuality of lifecancer; cardiovascular disease; contraception; hirsutism; insulin resistance; menopause; PCOS; pregnancy; quality of life; type 2 diabetescardiovascular diseaseNeoplasmsinsulin resistancePCOShirsutismhirsutismReproductive BiologyPolycystic ovary syndrome (PCOS)RehabilitationObstetrics and GynecologyObstetrics & GynecologyMiddle AgedMenopausePhenotypecontraceptionCardiovascular DiseasesPCOS Cardiovascular risk adolescence cancer obesityFemalepregnancytype 2 diabetesPolycystic Ovary SyndromeAdultmedicine.medical_specialtyConsensusAdolescentDiabetes ComplicationsInsulin resistanceSDG 3 - Good Health and Well-beingmedicineHumanscancerMenstrual CycleAgedGynecologyPregnancybusiness.industryCancermedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaReproductive MedicineDiabetes Mellitus Type 2quality of lifeWomen's Healthbusiness
researchProduct

Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidis…

2020

High levels of LDL cholesterol (LDL-C) represent a causal factor for cardiovascular diseases on an atherosclerotic basis, with a direct correlation between these and mortality or cardiovascular events, such that the reduction of both is associated proportionally and linearly with the reduction of LDL-C.Statins and ezetimibe are used for LDL-C lowering but may not be sufficient to achieve the targets defined by the ESC/EAS guidelines, which recommend use of PCSK9 inhibitors for further LDL-C reduction in patients not at goal.This project submitted 86 clinical scenarios to a group of experts, cardiologists, internists and lipidologists, collecting their opinion on the appropriateness of diffe…

Settore MED/09 - Medicina InternaConsensusPCSK9 inhibitorFamilial hypercholesterolemiaHypercholesterolemiaAntibodies Monoclonal Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol LDL; Consensus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Risk Assessment; Risk Factors; Cardiovascular DiseasesConsensuAntibodies Monoclonal HumanizedRisk AssessmentAntibodiesLDLAcute coronary syndrome; Alirocumab; Cardiovascular risk; Familial hypercholesterolemia; PCSK9 inhibitors; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Atherosclerosis; Cholesterol LDL; Consensus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Risk Assessment; Risk Factors; Cardiovascular DiseasesRisk FactorsAnticholesteremic AgentMonoclonalHumansHumanizedAnticholesteremic AgentsCholesterol LDLCardiovascular riskAtherosclerosisCholesterolItalyPCSK9 inhibitorsCardiovascular DiseasesAtherosclerosiAcute coronary syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsAlirocumab
researchProduct

Lipid peroxidation and protein oxidation are related to the severity of OSAS

2014

OBJECTIVE: Obstructive sleep apnea syndrome (OSAS) is associated with elevated cardiovascular morbidity and mortality. Considering that oxidative stress is involved in endothelial dysfunction and atherosclerosis development, our aim was to examine lipid peroxidation and protein oxidation, two parameters of oxidative status, in a group of subjects with OSAS. PATIENTS AND METHODS: We consecutively enrolled 48 patients (36 men and 12 women; mean age 49.7±14.6 yrs) with OSAS, subsequently subdivided according to the apnea/hy-popnea index (AHI) value in two subgroups: Low (L= 21 subjects with AHI30). We examined lipid peroxidation, expressed as TBARS, and protein oxidation, measured as carbonyl …

Settore MED/09 - Medicina InternaMedicine (all)Lipid peroxidationOSASPharmacology (medical)Cardiovascular riskCardiovascular risk; Lipid peroxidation; OSAS; Protein oxidation; Medicine (all); Pharmacology (medical)Protein oxidation
researchProduct